News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

September 4, 2018 Apellis Pharmaceuticals Announces that All Four Severely Anemic Soliris™-Treated Patients with Paroxysmal Nocturnal Hemoglobinuria in Ongoing Phase 1b Trial Have Been Transitioned to APL-2 Monotherapy
July 31, 2018 Apellis Pharmaceuticals Reports Second Quarter 2018 Business Update and Financial Results
July 24, 2018 Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from FDA for the Treatment of Patients with Geographic Atrophy
June 26, 2018 Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
June 26, 2018 Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 19, 2018 Apellis Pharmaceuticals to Host R&D Day on June 26, 2018
May 31, 2018 Apellis Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
April 30, 2018 Apellis Pharmaceuticals Reports First Quarter 2018 Business Update and Financial Results
April 23, 2018 Apellis Pharmaceuticals Announces Closing of Offering of Common Stock
April 18, 2018 Apellis Pharmaceuticals Announces Pricing of Offering of Common Stock